Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 17, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes and Transactions
The filing details several transactions executed by Abacus (GSK) Trustees Limited on behalf of the GlaxoSmithKline Employee Trust ("the GSK Trust") for employee incentive plans:
- February 10, 2006: Transferred 211,612 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- February 10, 2006: Sold 3,410 ADSs on behalf of the SmithKline Beecham Mid-Term Incentive Plan at $51.61 per ADS.
- February 10, 2006: Transferred 7,145 ADSs to participants in the SmithKline Beecham Mid-Term Incentive Plan.
- February 13, 2006: Sold 2,398 ADSs on behalf of the SmithKline Beecham Mid-Term Incentive Plan at $51.15 per ADS.
- February 13, 2006: Transferred 5,650 ADSs to participants in the SmithKline Beecham Mid-Term Incentive Plan.
- February 14, 2006: Transferred 62,112 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- February 15, 2006: Transferred 12,890 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding the company's operations are disclosed in this text.
Investor Verification Points
- Verify the total volume of shares transferred versus sold to understand the net impact on the company's share count.
- Confirm the pricing of ADS sales ($51.61 and $51.15) against market prices on the transaction dates.
- Review the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 and Mid-Term Incentive Plan to understand vesting conditions.
- Check subsequent filings for any changes in the beneficial ownership of the three named directors.